Program
ivosidenib
Also written as “Ivosidenib”, “Ivosidenib Oral Tablet” and “AG120”.
Its studies are mostly in Cholangiocarcinoma · Leukemia, Myeloid, Acute · Neoplasm Metastasis · Neoplasms, Unknown Primary, led by 6 companies.
Drug pageIvosidenib: every studyMany companies study it; this page follows only the 13 they lead. All 55 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticalsits history only | 50 open or running | phase 1since Jul 1, 2015 | Jul 1, 2015 | none ahead |
| Servier Bio-Innovationits history only | 32 open or running | phase 3since Nov 7, 2023 | Apr 21, 2023 | Feb 1, 2028phase 3 · NCT06127407 |
| Servier Affaires Médicalesits history only | 22 open or running | phase 3since May 17, 2023 | May 17, 2023 | Oct 15, 2027phase 3 · NCT05907057 |
| CStone Pharmaceuticalsits history only | 10 open or running | phase 1since Oct 29, 2019 | Oct 29, 2019 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Apr 5, 2018 | Apr 5, 2018 | none ahead |
| Servierits history only | 11 open or running | phase 2since Sep 14, 2023 | Sep 14, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 1, 2015First study: phase 1 study in Healthy VolunteersNew to Agios PharmaceuticalsAgios Pharmaceuticals · NCT02489513 · 8 enrolled · United States
- Oct 15, 2015Phase 1 study in HealthyAgios Pharmaceuticals · NCT02579707 · 36 enrolled · United States
- Dec 9, 2015Named ivosidenibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, AG120
- Jun 9, 2016Phase 1 study in HealthyAgios Pharmaceuticals · NCT02831972 · 22 enrolled · United States
- Mar 2, 2017Phase 1 study in HealthyAgios Pharmaceuticals · NCT03071770 · 60 enrolled · United States
- Sep 8, 2017Phase 1 study in Hepatic ImpairmentAgios Pharmaceuticals · NCT03282513 · 33 enrolled · United States
- Apr 5, 2018Hoffmann-La Roche’s first study: phase 2 study in Neoplasms, Unknown PrimaryNew to Hoffmann-La RocheHoffmann-La Roche · NCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
- Oct 29, 2019CStone Pharmaceuticals’ first study: phase 1 study in RecurrenceNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT04176393 · 30 enrolled · China
- Apr 21, 2023Servier Bio-Innovation’s first study: phase 2 study in IDH1-mutant CholangiocarcinomaNew to Servier Bio-InnovationServier Bio-Innovation · NCT05921760 · 7 enrolled · United States, United Kingdom
- May 17, 2023Servier Affaires Médicales’ first study: phase 3 study in CholangiocarcinomaNew to Servier Affaires MédicalesServier Affaires Médicales · NCT05876754 · 299 enrolled · Armenia, Australia, Austria and more
- Jun 8, 2023Phase 3 study in Leukemia, Myeloid, AcuteServier Affaires Médicales · NCT05907057 · 245 planned · Austria, France, Italy and more
- Sep 14, 2023Servier’s first study: phase 2 study in Cholangiocarcinoma Non-resectableNew to ServierServier · NCT06081829 · 12 enrolled · Japan
- Nov 7, 2023Phase 3 study in Neoplasm MetastasisServier Bio-Innovation · NCT06127407 · 156 planned · United States, Australia, Belgium and more
- May 27, 2025Phase 1 study in IDH1-Mutated MalignanciesServier Bio-Innovation · NCT07006688 · 30 planned · United States, Australia, Brazil and more
Ahead
- Oct 15, 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteServier Affaires Médicales · NCT05907057
- Dec 1, 2027Primary completion: phase 3 study in CholangiocarcinomaServier Affaires Médicales · NCT05876754
- Feb 1, 2028Primary completion: phase 3 study in Neoplasm MetastasisServier Bio-Innovation · NCT06127407
- Jul 31, 2028Primary completion: phase 1 study in IDH1-Mutated MalignanciesServier Bio-Innovation · NCT07006688
TargetBeta
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on IDH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olutasidenibrule | Rigel Pharmaceuticals | phase 4 | 5 |
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 12 |
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
| safusidenibrule | Nuvation Bio | phase 3 | 6 |
| IDH1 Inhibitor TQB3454 | Sino Biopharmaceutical | phase 3 | 5 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07006688IDH1-Mutated Malignancies · United States, Australia, Brazil and more | 1 | Recruiting | Servier Bio-Innovation | Jul 31, 2028 | 30 |
| NCT06127407Neoplasm Metastasis · United States, Australia, Belgium and more | 3 | Recruiting | Servier Bio-Innovation | Feb 1, 2028 | 156 |
| NCT06081829Cholangiocarcinoma Non-resectable · Japan | 2 | Active, not recruiting | Servier | Oct 1, 2024 | 12 |
| NCT05907057Leukemia, Myeloid, Acute · Austria, France, Italy and more | 3 | Recruiting | Servier Affaires Médicales | Oct 15, 2027 | 245 |
| NCT05876754Cholangiocarcinoma · Armenia, Australia, Austria and more | 3 | Active, not recruiting | Servier Affaires Médicales | Dec 1, 2027 | 299 |
| NCT05921760IDH1-mutant Cholangiocarcinoma · United States, United Kingdom | 2 | Terminated | Servier Bio-Innovation | Nov 21, 2024 | 7 |
| NCT04176393Recurrence · China | 1 | Completed | CStone Pharmaceuticals | Feb 18, 2021 | 30 |
| NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more | 2 | Completed | Hoffmann-La Roche | Feb 14, 2023 | 529 |
| NCT03282513Hepatic Impairment · United States | 1 | Completed | Agios Pharmaceuticals | Mar 31, 2018 | 33 |
| NCT03071770Healthy · United States | 1 | Completed | Agios Pharmaceuticals | May 9, 2017 | 60 |
| NCT02831972Healthy · United States | 1 | Completed | Agios Pharmaceuticals | Sep 2016 | 22 |
| NCT02579707Healthy · United States | 1 | Completed | Agios Pharmaceuticals | Feb 2016 | 36 |
| NCT02489513Healthy Volunteers · United States | 1 | Completed | Agios Pharmaceuticals | Sep 2015 | 8 |
How it is read
Names in the registry
- “Ivosidenib”, 3 entries
- “Ivosidenib Oral Tablet”, 2 entries
- “AG120”, 2 entries
- “Ivosidenib 500mg”, 1 entry
- “Ivosidenib 500mg Oral Tablet”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 3 studies
- Leukemia, Myeloid, Acute, 2 studies
- Neoplasm Metastasis, 1 study
- Neoplasms, Unknown Primary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.